Form 4: Eli Lilly EVP & CFO Lucas Montarce Reports Stock Acquisition
SEC Form 4 Filing
Lucas Montarce, EVP & CFO of Eli Lilly & Co, reports acquiring 2,895.932 shares of common stock at $868.88 per share on February 10, 2025.
Summary
- On February 10, 2025, Lucas Montarce, the EVP & CFO of Eli Lilly & Co, acquired 2,895.932 shares of common stock.
- The acquisition price was $868.88 per share.
- Following the transaction, Montarce directly owns 13,969.736 shares of Eli Lilly & Co.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of an insider transaction. The purchase itself is a slightly positive signal, but not significantly so.
Positives
- The purchase of shares by a high-ranking executive could be interpreted positively, signaling confidence in the company's future performance.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of the stock acquisition transaction. |
| 02/12/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, insider trading, stock acquisition, Lucas Montarce, LLY, Eli Lilly & Co, EVP & CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.